Cargando…
S197: LINKER-MM1 STUDY: LINVOSELTAMAB (REGN5458) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
Autores principales: | Lee, Hans C., Bumma, Naresh, Richter, Joshua, Dhodapkar, Madhav, Hoffman, James E., Suvannasankha, Attaya, Zonder, Jeffrey, Shah, Mansi R., Lentzsch, Suzanne, Maly, Joseph J., Ye, Jing Christine, Wu, Ka Lung, Deveaux, Michelle, Chokshi, Dhruti, Boyapati, Anita, Hazra, Anasuya, Lorenc, Karen Rodriguez, Kroog, Glenn, Houvras, Yariv, Jagannath, Sundar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428402/ http://dx.doi.org/10.1097/01.HS9.0000967700.16100.68 |
Ejemplares similares
-
PB2144: TRIAL IN PROGRESS: A PHASE 1/2 WINDOW OF OPPORTUNITY STUDY OF THE BCMAXCD3 BISPECIFIC ANTIBODY LINVOSELTAMAB IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA
por: Ferreri, Christopher J., et al.
Publicado: (2023) -
PB2133: TRIAL IN PROGRESS: LINKER-MM3, A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF LINVOSELTAMAB VERSUS ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
por: Weisel, Katja, et al.
Publicado: (2023) -
Acquired Factor X Deficiency in Patients With Primary Light Chain Amyloidosis
por: Dejhansathit, Siroj, et al.
Publicado: (2019) -
Role of bone-anabolic agents in the treatment of breast cancer bone metastases
por: Suvannasankha, Attaya, et al.
Publicado: (2014) -
REGN-EB3: First Approval
por: Markham, Anthony
Publicado: (2021)